NSCLC

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

RET Inhibitors Active in Proportion of Patients with RET-Rearranged NSCLC

By

The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.

Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC

Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC

By

The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.

Expression Levels of SMARCA4/BRG1 Gene Indicates Response to Chemotherapy

By

Significant sensitivity to cisplatin-based chemotherapy is signaled by the presence of low expression of SMARCA4/BRG1 in patients with earlier-stage NSCLC. Low expression of SMARCA4/BRG1 was also linked to a poor prognosis.

Combination of Immune Checkpoint Blockers Shows Promise in Lung Cancer

By

Combination therapy with durvalumab and tremelimumab demonstrated antitumor activity in 23% of 102 patients with lung cancer in a phase 1b trial, and toxicity was manageable.

Newly Approved NSCLC Diagnostic Assay Accurately Assesses for Treatment Options

By

An immunohistochemistry (IHC) test for rearrangements of the gene for anaplastic lymphoma kinase (ALK) receptor performed more accurately than another commonly used IHC assay, including reducing the rate of false positives.

Outcomes Are Comparable With Treatment Allocation Based on CGA or Performance Status and Age in Elderly Patients with NSCLC

Outcomes Are Comparable With Treatment Allocation Based on CGA or Performance Status and Age in Elderly Patients with NSCLC

By

Treatment allocation based on comprehensive geriatric assessment (CGA) did not improve treatment failure free survival or overall survival, but treatment toxicity was slightly reduced, in elderly patients with NSCLC.

NSCLC: Bevacizumab Beyond Disease Progression After First-line Bevacizumab

NSCLC: Bevacizumab Beyond Disease Progression After First-line Bevacizumab

By

Addition of bevacizumab to chemotherapy beyond disease progression may be effective in patients with advanced non-small cell lung cancer (NSCLC).

Younger Age Linked With Targetable Genotype in NSCLC

By

Younger age is associated with an increased likelihood of having a targetable genotype in patients with non-small cell lung cancer (NSCLC).

SBRT Well Tolerated in Patients With Early Stage and Centrally Located NSCLC

By

Treatment with stereotactic body radiotherapy (SBRT) was well-tolerated by patients whose non-small cell lung cancer (NSCLC) tumors were located centrally in the chest and who were not candidates for surgery.

Rare Mutation May Extend Survival in Lung Cancer Patients With Brain Metastases

Rare Mutation May Extend Survival in Lung Cancer Patients With Brain Metastases

By

Most patients with NSCLC that has metastasized to the brain have a dire prognosis. However, researchers have identified a subset of those patients who have a rare genetic mutation and are living significantly longer than patients without the mutation.

Intensity-Modulated Radiation Lessens Side Effects for Lung Cancer Patients

Intensity-Modulated Radiation Lessens Side Effects for Lung Cancer Patients

By

An analysis of an international, cooperative-led trial of patients with locally advanced NSCLC has shown that those who received IMRT had less severe lung toxicity and were able to better tolerate their chemotherapy, compared with patients who received 3-D CRT.

Clinical Trial Demonstrates Superior Results With Immunotherapy vs Chemotherapy for Lung Cancer

By

An international team of cancer researchers announced game-changing results in the treatment of certain lung cancers with nivolumab compared with chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy.

Smokers and Nonsmokers Who Develop NSCLC Display Differences

Smokers and Nonsmokers Who Develop NSCLC Display Differences

Nonsmokers more likely than smokers to be women and to have adenocarcinoma

Novel diagnostic tool for ethnically diverse patients with non-small cell lung cancer

Novel diagnostic tool for ethnically diverse patients with non-small cell lung cancer

By

A panel of five serum microRNAs has been identified as a potential biomarker to diagnose early stage non-small cell lung cancer.

Breakthrough supportive care: Overcoming cancer anorexia/cachexia

Breakthrough supportive care: Overcoming cancer anorexia/cachexia

By

A new drug is proven to offer significantly better outcomes for patients with non-small cell lung cancer who experience this debilitating side effect.

Multimodality treatment for metastatic lung cancer with surgery may improve survival

By

Patients with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection of all or part of the lung if combined with chemotherapy and radiation therapy.

Next-generation ALK-inhibitor brigatinib promising against NSCLC

By

Clinical trial results showed good performance employing the investigational drug brigatinib against ALK-positive non-small cell lung cancer (NSCLC).

Immunotherapy drug improves survival for common form of lung cancer

By

Individuals with squamous non-small cell lung cancer (NSCLC) fared better when receiving nivolumab when compared to those receiving more standard chemotherapy, according to a recent clinical trial.

Stereotactic ablative radiotherapy (SABR) offers better overall survival than surgery in early lung cancer

Stereotactic ablative radiotherapy (SABR) offers better overall survival than surgery in early lung cancer

By

Patients with operable stage I non-small cell lung cancer can achieve better overall survival rates if treated with stereotactic ablative radiotherapy (SABR) opposed to the current standard therapy.

Phase I trial of lung cancer drug identifies multiple types of drug resistance

By

Researchers urge for new targeted inhibitors and combinations to combat tumors' constant and varied molecular adaptation.

Liquid biopsy: A new tool in the management of NSCLC

Liquid biopsy: A new tool in the management of NSCLC

By

This developing technology allows serial monitoring to better gauge response to treatment and prognosis for patients with non-small cell lung cancer.

Mutation that drives NSCLC also found in one-quarter of small cell lung cancers

By

Research indicates that a known mutation in non-small cell lung cancer (NSCLC) is also present in small cell lung cancer, implying that some effective treatments for NSCLC can also be used on the more aggressive form of the disease.

Survival longer in patients with early stage non-small cell lung cancer (NSCLC) with low tumor metabolic activity

By

Increased overall survival and more time before tumor recurrence is associated with low presurgery uptake of a labeled glucose analogue in the primary tumor of patients with stage I non-small cell lung cancer.

Online education tool helps bridge gaps in therapeutic decision-making for NSCLC

By

A new online tool uses a patient's molecular characteristics and provides feedback from an expert panel to help oncologists with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC).

Blood samples may serve as surrogates for tumor biopsies in patients with lung cancer

By

A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small cell lung cancer as a surrogate for tumor biopsies.

Epigenetic drug boosts efficacy of chemotherapy in some lung cancers

Epigenetic drug boosts efficacy of chemotherapy in some lung cancers

By

An existing drug may assist patients with non-small cell lung cancer (NSCLC) that shows chemotherapy resistance.

Stereotactic body radiation therapy (SBRT) plus chemotherapy improves survival among patients with stage 4 lung cancer

By

Combining stereotactic body radiation therapy (SBRT) with a specific chemotherapy regimen more than doubled survival rates for certain patients with stage 4 lung cancer, according to recent research data.

Gefitinib effective in older, African American patients with non-small cell lung cancer (NSCLC)

By

Researchers have found that an FDA-approved therapy could be effective in treating both older and African American patients with advanced lung cancer who may not be candidates for chemotherapy.

Rociletinib produces response in treatment-resistant advanced non-small cell lung cancer (NSCLC)

By

A new drug that targets common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), and a type of the mutation responsible for treatment resistance, has shown promising results in a phase I/II clinical trial.

Treatment-resistant non-small cell lung cancer (NSCLC) responds to new drug

By

An oral drug called ASP8273 caused tumor shrinkage in patients in a phase I clinical trial, according to research presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs